Neurocrine Biosciences, Inc. Announces Results From Follow-Up Phase II Study With Its Orally Active GnRH Receptor Antagonist In Endometriosis

SAN DIEGO, Sept. 12 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - News) today announced positive safety and efficacy results with completion of the second off-treatment 3-month period of its 6-month 'proof of concept', safety, efficacy and dose-finding Phase II clinical trial using its proprietary, orally-active small molecule Gonadotropin-Releasing Hormone (GnRH) receptor antagonist (NBI-56418). The Company previously reported positive preliminary results from the completion of the first 3-month double-blind period of this Phase II trial in April 2006.